230295-16-6

Basic information

• Product Name: 4-Trifluoromethyl-3-fluorobenzyl alcohol
• Synonyms: 3-Fluoro-4-(trifluoromethyl)benzenemethanol;2-Fluoro-4-(hydroxymethyl)benzotrifluoride, [3-Fluoro-4-(trifluoromethyl)phenyl]methanol;3-Fluoro-4-(trifluoromethyl)benzylalcohol97%;(3-Fluoro-4-(trifluoromethyl)phenyl)methanol
• CAS NO: 230295-16-6
• Molecular Formula: C₈H₆F₄O
• Molecular Weight: 194.13
• Product Categories: Fluorine series
• Mol File: 230295-16-6.mol
• Article Data: 5

Chemical Properties

• Melting Point: 28-32°C
• Boiling Point: 209℃
• Flash Point: 80℃
• Appearance: /
• Density: 1.377
• Vapor Pressure: 0.128mmHg at 25°C
• Refractive Index: 1.447
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 13.76±0.10(Predicted)
• CAS DataBase Reference: 4-Trifluoromethyl-3-fluorobenzyl alcohol(CAS DataBase Reference)
• NIST Chemistry Reference: 4-Trifluoromethyl-3-fluorobenzyl alcohol(230295-16-6)
• EPA Substance Registry System: 4-Trifluoromethyl-3-fluorobenzyl alcohol(230295-16-6)

Safety Data

• Hazardous Substances Data: 230295-16-6(Hazardous Substances Data)

Usage

Description

4-Trifluoromethyl-3-fluorobenzyl alcohol is a chemical compound characterized by the molecular formula C8H6F4O. It is a white crystalline solid that is widely recognized for its unique properties and versatile applications in various fields.

Uses

Used in Organic Synthesis:
4-Trifluoromethyl-3-fluorobenzyl alcohol is used as a building block in organic synthesis for its ability to contribute to the formation of complex organic molecules. Its presence in the synthesis process can enhance the reactivity and selectivity of the reactions.
Used in Pharmaceutical Production:
In the pharmaceutical industry, 4-Trifluoromethyl-3-fluorobenzyl alcohol is utilized as a key intermediate in the production of various drugs. Its unique properties make it a valuable component in the development of new medications with improved efficacy and selectivity.
Used as a Chiral Auxiliary:
4-Trifluoromethyl-3-fluorobenzyl alcohol is employed as a chiral auxiliary in asymmetric synthesis reactions. Its chiral nature allows for the selective formation of enantiomers, which is crucial in the synthesis of biologically active compounds that require specific stereochemistry.
Used in Agrochemicals:
4-Trifluoromethyl-3-fluorobenzyl alcohol is also used in the agrochemical industry, where it serves as a building block for the synthesis of various agrochemicals. Its incorporation can lead to the development of more effective and targeted pesticides and other agricultural products.
Used in Material Science:
4-Trifluoromethyl-3-fluorobenzyl alcohol has potential applications in the development of new materials. Its unique properties can be harnessed to create materials with specific characteristics, such as improved stability or reactivity.
Used in Medicinal Chemistry Research:
In the field of medicinal chemistry, 4-Trifluoromethyl-3-fluorobenzyl alcohol is used as a reagent in the synthesis of various organic compounds. Its versatile reactivity makes it a valuable tool in the discovery and development of new pharmaceutical agents.

InChI:InChI=1/C8H6F4O/c9-7-3-5(4-13)1-2-6(7)8(10,11)12/h1-3,13H,4H2

Upstream product

• 773873-89-5 methyl 3-fluoro-4-(trifluoromethyl)benzoate 
• 204339-72-0 3-fluoro-4-trifluoromethyl-benzaldehyde 
• 115754-21-7 3-fluoro-4-(trifluoromethyl)benzoic acid 

Downstream Products

• 1610416-86-8 2-fluoro-4-(methoxymethyl)-1-(trifluoromethyl)benzene 
• 1610415-41-2 1-(1',4-dimethyl-1-phenyl-1H,1'H-[3,4'-bipyrazol]-5-yl)-3-(5-(methoxymethyl)-2-(trifluoromethyl)benzyl)urea 
• 1610416-87-9 5-(methoxymethyl)-2-(trifluoromethyl)benzonitrile 
• 1610416-88-0 (5-(methoxymethyl)-2-(trifluoromethyl)phenyl)methanamine 
• 1621222-25-0 (R)-6-((1-cyclobutylethyl)amino)-7-(3-fluoro-4-(trifluoromethyl)benzyl)-7H-purine-2-carbonitrile 
• 1621222-27-2 (R)-2-chloro-N-(1-cyclobutylethyl)-7-(3-fluoro-4-(trifluoromethyl)benzyl)-7H-purin-6-amine 
• 1621222-26-1 2,6-dichloro-7-(3-fluoro-4-(trifluoromethyl)benzyl)-7H-purine 
• 213203-65-7 4-(bromomethyl)-2-fluoro-1-(trifluoromethyl)benzene 
• 444915-54-2 4-(chloromethyl)-2-fluoro-1-(trifluoromethyl)benzene 
• 478373-37-4 {4'-methoxy-3'-[(3-fluoro-4-trifluoromethyl-benzyloxycarbonylamino)methyl]biphenyl-3yl}acetic acid 
• 478373-87-4 2-{4'-Methoxy-3'-[(3-fluoro-4-trifluoromethylbenzyloxycarbonylamino)methyl]biphenyl-3-yl}propionic acid 
• 478373-57-8 {4'-Ethoxy-3'-[(3-fluoro-4-trifluoromethylbenzyloxycarbonylamino)methyl]biphenyl-3-yl}-acetic acid 

Relevant articles and documents

Design, Synthesis, and in vitro Evaluation of P2X7 Antagonists

The P2X7 receptor is a promising target for the treatment of various diseases due to its significant role in inflammation and immune cell signaling. This work describes the design, synthesis, and in vitro evaluation of a series of novel derivatives bearing diverse scaffolds as potent P2X7 antagonists. Our approach was based on structural modifications of reported (adamantan-1-yl)methylbenzamides able to inhibit the receptor activation. The adamantane moieties and the amide bond were replaced, and the replacements were evaluated by a ligand-based pharmacophore model. The antagonistic potency of the synthesized analogues was assessed by two-electrode voltage clamp experiments, using Xenopus laevis oocytes that express the human P2X7 receptor. SAR studies suggested that the replacement of the adamantane ring by an aryl-cyclohexyl moiety afforded the most potent antagonists against the activation of the P2X7 cation channel, with analogue 2-chloro-N-[1-(3-(nitrooxymethyl)phenyl)cyclohexyl)methyl]benzamide (56) exhibiting the best potency with an IC50 value of 0.39 μΜ.

N-(ARYLALKYL)-N'-PYRAZOLYL-UREA, THIOUREA, GUANIDINE AND CYANOGUANIDINE COMPOUNDS AS TRKA KINASE INHIBITORS

Compounds of Formula I or stereoisomers, tautomers, or pharmaceutically acceptable salts, solvates or prodrugs thereof, wherein Ring A, Ring C, X, Ra, Rb, Rc, Rd and n are as defined herein, are inhibitors of TrkA kinase and are useful in the treatment of diseases which can be treated with a TrkA kinase inhibitor such as pain, cancer, inflammation/inflammatory diseases, neurodegenerative diseases, certain infectious diseases, Sjogren's syndrome, endometriosis, diabetic peripheral neuropathy, prostatitis or pelvic pain syndrome.

AMINOETHANOL DERIVATIVES

The present invention provides a pharmaceutical agent having cholesteryl ester transfer protein inhibitory action and useful as a blood lipid lowering agent and the like. The present invention relates to a compound represented by the formula wherein Ar1 is an aromatic ring group optionally having substituents, Ar2 is an aromatic ring group having substituents, OR'' is an optionally protected hydroxyl group, R is an acyl group, R' is a hydrogen atom or a hydrocarbon group optionally having substituents, or a salt thereof, and a pharmaceutical composition containing a compound of the formula (I) or a salt thereof or a prodrug thereof.